Human cytomegalovirus (HCMV) and herpes simplex virus (HSV) can cause a wide variety of clinical manifestations in man. Ganciclovir (GCV) is effective against HCMV infection when administered by the intravenous route and may be used orally in large doses for prophylaxis of HCMV infections in organ transplantation patients and in AIDS patients. In previous studies with acyclovir (ACV), we found that covalent attachment of an alkyl glycerol phosphate moiety greatly increased oral bioavailability and increased antiviral activity against hepatitis B virus. Adducts of ACV with alkyl propanediol phosphate were more active than the alkyl glycerol phosphate analogue in vitro in 2.2.15 cells, which constitutively produce hepatitis B virus. To see if this strategy would work for two other poorly absorbed nucleoside analogues, we synthesized 1-O-hexadecylpropanediol-3-phospho-GCV (HDP-P-GCV) and 1-O-hexadecyl-propanediol-3-phospho-penciclovir (HDP-P-PCV), and evaluated the in vitro antiviral activity, selectivity and oral antiviral activity of both compounds versus GCV or PCV in mice infected with HSV-1 or HDP-P-GCV versus murine cytomegalovirus (MCMV). HDP-P-GCV is orally active in both MCMV and HSV-1 infection in mice with antiviral activity equivalent to (HSV-1) or greater than oral GCV (MCMV). Oral HDP-P-PCV was more active than PCV orally versus intranasal HSV-1 infection in mice.
Cytomegalovirus (CMV) retinitis is the most common opportunistic eye infection in HIV-positive individuals and prior to highly active antiretroviral therapy (HAART), it was encountered in an estimated 20-40% of AIDS patients ( Jacobson & Mills, 1988; Drew, 1988; Gallant et al., 1992) . Currently, three major drugs are approved for treatment of CMV retinitis in AIDS, ganciclovir (GCV), foscarnet and cidofovir ( Jacobson et al., 1989; Spector et al., 1993; Hitchcock et al., 1996) . These drugs require intravenous administration, but they do not eliminate virus from the retina, requiring long-term suppressive maintenance therapy. Relapse is frequent in non-immune reconstituted patients and systemic toxicity to bone marrow (neutropenia, GCV) and kidneys (foscarnet, GCV and cidofovir) can be problematic (Shepp et al., 1985; Chrisp & Clissold, 1991; Lalezari et al., 1997) .
Ganciclovir, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, an analogue of 2-deoxyguanine, inhibits the replication of herpes group viruses including herpes simplex virus types 1 and 2 (HSV-1 and HSV-2, respectively) and human CMV (HCMV) (Biron et al., 1985; Cole & Balfour, 1987; Faulds & Heel, 1990) . In HCMV-infected cells, GCV is phosphorylated to GCV monophosphate by a protein kinase coded for by the UL97 gene (Littler et al., 1992; Sullivan et al., 1992) . After conversion to GCV triphosphate by cellular kinases, GCV-TP competitively inhibits viral DNA polymerase activity (Matthews & Boehme, 1988) .
Ganciclovir may be administered orally in high doses (1g, three times daily) for CMV prophylaxis in transplant (Flechner et al., 1998; Singh et al., 2000) , but must be given intravenously to treat HCMV-infected patients because oral absorption of GCV in man is very low (6%) ( Jacobson et al., 1987) . Intravenous GCV is effective in treating AIDS-related CMV infections such as retinitis, pneumonia and GI disease, and is also effective in posttransplant CMV infections (Reviewed in Faulds & Heel, 1990 ). As noted above, GCV is used in large oral doses for prophylaxis and maintenance therapy in immunosuppressed transplant patients, but the drug levels achieved orally are insufficient to treat active CMV disease (Spector et al., 1995) .
It would be useful to have a method for making poorly absorbed nucleosides, such as GCV or PCV, orally bioavailable while allowing for direct metabolism to their monophosphates in liver. We reported previously that 1-O-octadecyl-sn-glycero-3-phospho-acyclovir (ODG-P-ACV ), an alkyl ether phospholipid analogue of acyclovir (ACV) was 100% orally absorbed and was converted in part to acyclovir monophosphate in hep-G2 cells (Hostetler et al., 1997) . 1-O-Hexadecylpropanediol-3-phospho-ACV, a related compound lacking a hydroxyl at the sn-2 carbon of glycerol, was more potent in vitro in 2.2.15 cells and was also orally active in woodchuck hepatitis virus-infected woodchucks (Hostetler et al., 2000) .
To extend these observations, we synthesized the ganciclovir analogue, 1-O-hexadecylpropanediol-3-phospho-GCV (HDP-P-GCV), and the penciclovir analogue, 1-Ohexadecylpropanediol-3-phospho-penciclovir (HDP-P-PCV), and studied their in vitro antiviral activity in HCMV-, HSV-1-, HSV-2-and murine CMV (MCMV)-infected cells. To evaluate the effect of HDP-P-GCV in animal models of disease, we examined the effect of oral HDP-P-GCV or GCV treatment on acute infection of mice with HSV -1 or with MCMV. Figure 1 . Synthesis of 1-O-Hexadecylpropanediol-3-phospho-ganciclovir and -penciclovir
HDP-P-GCV X = 0 HDP-P-PCV X = CH 2
Reagents: (a) POCl 3 , TEA, THF; (b) N-MMTr-ganciclovir or N-MMTr-penciclovir, DCC (two equivalents), pyridine; (c) 80% aqueous acetic acid, 60°C; (d) 2N NaOH, 50°C.
Activity of nucleoside analogues against CMV and HSV
Materials and Methods

Chemistry
General. Harnden et al. (1987) and 3-hexadecyloxy-propan-1-ol was prepared as previously described by Kini et al. (1997a) . All other reagents were obtained from Aldrich Chemical Co. unless otherwise noted.
3-Hexadecyloxy-propyl phosphate. A solution of POCl 3 (4.6 g, 30 mmol) in THF (100 ml) was cooled to 0°C with an ice/methanol bath. A solution of 3-hexadecyloxy-1-propanol (6.0 g, 20 mmol) and triethylamine (3.0 g, 30 mmol) in THF (50 ml) was added dropwise over 20 min, then the ice bath was removed and the mixture stirred for an additional 2 h. The mixture was then poured into crushed ice and the solid that separated was collected by vacuum filtration, rinsed with water and dried thoroughly in vacuo. The crude product was recrystallized from hexanes to yield 5.4 g (72%) 3-hexadecyloxy-propyl phosphate as a white powder.
1 H NMR (CDCl 3 ) δ 9.22 (s, 2H), 4.06 (q, 2H), 3.51 (t, 2H), 3.39 (t, 2H), 1.92 (p, 2H), 1.52 (m, 2H), 1.26 (br s 14H), 0.88 (t, 3H); 31 P NMR δ +1.41. (N-MMTr-GCV) . To ganciclovir (4.4 g, 17 mmol) suspended in 100 ml of dry pyridine and cooled to 0°C was slowly added chlorotrimethylsilane (11.2 g, 103 mmol). After stirring the mixture for 15 min, monomethoxytrityl chloride (Fluka, 6.18 g, 20 mmol) and N,N-dimethylaminopyridine (0.25 g, 2 mmol) were added and the reaction was allowed to warm to room temperature and stirred for 18 h. The mixture was then cooled to 5°C with an ice/H 2 O bath and water (20 ml) was added. After 10 min 29% aqueous NH 4 OH (25 ml) was added and the mixture was stirred for 15 min. The reaction was filtered and the filtrate evaporated. The residue was purified by flash chromatography using 1:5 ethanol/ethyl acetate to elute 5.2 g (58% yield) of N-MMTr-GCV as a foamy solid. Stirring the solid in toluene while heating gave crystalline product. -[4-hydroxy-3-(hydroxymethyl)but-1-yl] guanine (N-MMTr-PCV) . To penciclovir (22 g, 87 mmol), suspended in dry pyridine (640 ml) and cooled to 0°C, was slowly added chlorotrimethylsilane (64.2 g, in 640 ml of 590 mmol). After stirring the mixture for 15 min, monomethoxytrityl chloride (Fluka, 31.2 g, 101 mmol) and N,N-dimethylamino-pyridine (1.38 g, 11 mmol) were added and the reaction was allowed to warm to room temperature and stirred for 18 h. The mixture was then cooled to 5°C with an ice/H 2 O bath and water (110 ml) was added. After 10 min, 29% aqueous NH 4 OH (128 ml) was added and the mixture was stirred for 15 min. The reaction was filtered and the filtrate concentrated. The residue was purified by flash chromatography using 1:2 ethanol/CH 2 Cl 2 to elute 26.2 g (58% yield) of N-MMTr-PCV as a foamy solid. Stirring with toluene while heating gave crystalline product. 
To a mixture of 3-hexadecyloxypropyl phosphate (25.0 g, 66 mmol) and N-MMTr-GCV (40.6 g, 77 mmol) in dry pyridine (600 ml) was added 1,3-dicyclohexylcarbodiimide (27.2 g, 132 mmol) and the mixture was stirred for 18 h, then quenched by the addition of water (10 ml). The mixture was filtered and the filtrate was evaporated and the residue chromatographed (gradient: CH 2 Cl 2 95:5 CH 2 Cl 2 /EtOH) to give the cyclic phosphate. 
To a mixture of 3-hexadecyloxypropyl phosphate (18.4 g, 57 mmol) and NMMTr-PCV (30g, 57 mmol) in dry pyridine (1500 ml) was added 1,3-dicyclohexylcarbodiimide (23.5 g, 114 mmol) and the mixture was stirred for 18 h, then quenched by the addition of water (10 ml). The mixture was filtered and the filtrate was evaporated to dryness and the residue chromatographed (gradient: CH 2 Cl 2 to 95:5 CH 2 Cl 2 / EtOH) to give the cyclic phosphate 12 g 1 H NMR (DMSO-d 6 ) δ 0.83 (t, 3H), 1.21 (br s, 28H), 1. 31 P NMR -6.69, -6.95.
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine (3-hexadecyloxypropyl) phosphate, sodium salt.
HDP-cyclicP-GCV (6.5 g, 10.8 mmol) was suspended in 2 N NaOH and stirred and heated to 65°C for 1 h. The mixture was then cooled to 25°C and the pH was adjusted to 8 with 50% aq acetic acid. The solid that separated was collected by filtration, dried and recrystallized (2:1 p-dioxane/water) to give HDP-P-GCV as the sodium salt (5.4 g, 78% 
Preparation of drug-containing liposomes for antiviral assays
For the in vitro studies, HDP-P-GCV or HDP-P-PCV were incorporated into liposomes. Chloroform solutions of the phospholipids, cholesterol and drugs were mixed to provide dioleoylphosphatidylcholine, dioleoylphosphatidylglycerol, cholesterol and HDP-P-GCV or HDP-P-PCV, at a molar ratio of 50/10/30/10. Table 1 . Antiviral activity of GCV HDP-P-GCV and PCV and HDP-P-PCV in HCMV-and HSV-1-infected cells measured by viral DNA reduction assays GCV, ganciclovir; PCV, penciclovir; HDP-P-GCV, 1-O-hexadecyloxypropyl-3-phosphoganciclovir; HDP-P-PCV, 1-O-hexadecyoxypropyl-Ppenciclovir; EC 50 , the µM concentration of drug that reduces viral DNA by 50%; TC 50 , the µM concentration of drug that reduces viable cell number of MRC-5 cells by 50%. Data expressed as mean ± standard deviation. The number of replicate determinations is indicated in parentheses. Cytotoxicity assays were carried out two or three times. The selectivity index is the TC 50 /EC 50 .
Antiviral assays for HCMV, HSV-1 and MCMV, in vitro
Antiviral activity against HCMV or HSV-1 was determined by a DNA reduction assay in MRC-5 human lung fibroblasts using DNA probes supplied by Diagnostic Hybrids, Athens, OH as previously described (Hostetler et al., 1996; Kini et al., 1997) or by plaque reduction in human foreskin fibroblast (HFF) cells infected with HSV-1, E-377 strain or HSV-2, MS strain (Kern et al., 1973) . The antiviral activity of HDP-P-GCV was also determined in HCMV-infected human foreskin fibroblast (HFF) cells and MCMV-infected mouse embryo fibroblast (MEF) cells by plaque reduction assays (Qui et al., 1998) . Results are presented as the 50% effective concentration (EC 50 ) determined by regression analysis.
Cytotoxicity testing
We exposed MRC-5, HFF or MEF cells to the respective drugs, and evaluated the cytotoxic concentration of the agent that reduced viable cell number by 50% (TC 50 ) using a neutral red uptake assay as reported previously (Qui et al., 1998) .
Antiviral evaluations in vivo
For in vivo studies, HDP-P-GCV or HDP-P-PCV were aliquoted into daily dose vials for each concentration, to which the appropriate amount of sterile water was added. The drug was sonicated at room temperature (20-40°C) for 45 min using a Branson 3210 Ultrasonic Cleaner (Ultrasonics Corp., Danbury, Conn., USA), vortexed for 1 min, and then sonicated for an additional 15 min. GCV or PCV were dissolved in sterile water. Three-week-old female BALB/c mice were obtained from Charles River Breeding Laboratories, Raleigh, NC. Unanaesthetized mice were inoculated intranasally with 1.0×10 5 plaque-forming units (pfu) of HSV-1 strain E-377, in a volume of 0.04 ml (0.02 ml in each nostril) or intraperitoneally with 2.0×10 5 pfu of MCMV, strain Smith, in a volume of 0.1 ml. Unless otherwise indicated, compounds were administered orally twice daily (approximately at 8:00 am and 6:00 pm) for 7 days in 0.1 ml doses, beginning 24 h after viral inoculation. Prior to performing efficacy experiments, the toxicity of each drug was determined. The compounds were not toxic at the concentrations tested. Animals were monitored daily for 21 days.
Evaluation of efficacy and statistics
In the in vitro studies, the 50% effective concentration (EC 50 ) and 50% toxic concentration (TC 50 ) were determined versus the no-drug control, and the mean and standard deviation determined by Student's t-test of the unpaired means or using a computer program, MacSynergy II. Therapeutic efficacy in HSV-1-and MCMV-infected mice was determined by comparing placebo treatment with GCV versus HDP-P-GCV or PCV versus HDP-P-PCV treatment. Final mortality rates and mean day of death (MDD) values were compared using Fisher's exact test and the Mann-Whitney U Sum Rank test, respectively. A P value of 0.05 or less was considered significant.
Results
In vitro antiviral activity
The antiviral activity of HDP-P-GCV was evaluated in HCMV-and HSV-1-infected human lung fibroblasts using a DNA reduction assay (Table 1) . HDP-P-GCV reduced formation of HCMV-specific DNA by 50% at Table 2 . Activity of HDP-P-GCV and HDP-P-PCV against herpes viruses using a plaque reduction assay GCV, ganciclovir; PCV, penciclovir; HDP-P-GCV, 1-O-hexadecyloxypropyl-3-phosphoganciclovir; HDP-P-PCV, 1-O-hexadecyoxypropyl-Ppenciclovir; EC 50 , the µM concentration of drug that reduces viral DNA by 50%; TC 50 , the µM concentration of drug that reduces viable cell number of MRC-5 cells by 50%. Data expressed as mean ± standard deviation. The number of replicate determinations is indicated in parentheses. Cytotoxicity assays were done 2 times. The selectivity index is the TC 50 /EC 50 .
0.6 µM versus 1.6 µM for GCV. In HSV-1-infected cells, GCV and HDP-P-GCV were similar in their antiviral activity, with EC 50 values of 0.032 and 0.023 µM, respectively. In MRC-5 human lung fibroblasts, the selectivity index for GCV was higher than with HDP-P-GCV, >625 versus 360 for HCMV, and >31000 versus 9391 for HSV-1. PCV was less active than either GCV or HDP-P-GCV, with an EC 50 of 0.25 µM. HDP-P-PCV was somewhat less active in vitro than PCV with an EC 50 of 0.70 µM.
The EC 50 values for HDP-P-GCV and HDP-P-PCV were also determined by plaque reduction assays in human foreskin fibroblast cells (HFF cells) ( Table 2 ). In HSV-1-and HSV-2-infected cells the EC 50 values were 1.1 and 1.5 µM, respectively, while the EC 50 for HCMV-infected cells was 3.3-6.8 µM for the Toledo and AD169 strains, respectively. In MEF cells infected with MCMV, antiviral activity of HDP-P-GCV was not detected with the EC 50 value being 105 µM. In HFF cells, PCV was active against HSV-1 and HSV-2 at EC 50 values of 8-13 µM (Table 2) , but HDP-P-PCV had little antiviral activity.
Assessment of oral bioavailability of HDP-P-GCV
A liposomal formulation of HDP-P-GCV (25 mg/kg) was administered intraperitoneally or orally to mice. Urine was collected for 72 h and the amount of GCV, the ultimate metabolite of HDP-P-GCV, was determined in the urine by HPLC. Urinary GCV following intraperitoneal administration of HDP-P-GCV was 1.34 versus 1.08 µM when the drug was given orally. Thus, the oral bioavailability of HDP-P-GCV is 81%. GCV oral bioavailability in mice measured by the same method was 39% (data not shown).
In vivo antiviral activity of HDP-P-GCV in HSV-1-infected mice
We administered HDP-P-GCV or GCV to mice infected with HSV-1 in twice-daily doses of 25, 12.5, 6.25 and 3.125 mg/kg for 7 days, beginning 24 h after viral inoculation (Table 3) . HDP-P-GCV was highly active at concentrations ranging from 25 to 6.25 mg/kg (P<0.0001 to <0.01). GCV exhibited similar activity, with the exception of additional efficacy at 3.125 mg/kg (P<0.001).
In the next experiment, HDP-P-GCV was evaluated orally in mice treated with lower doses: 12.8, 4.05, 1.28 or 0.41 mg/kg twice daily for 7 days ( Table 4 . Effect of oral treatment with HDP-P-GCV or GCV on the mortality of BALB/c mice inoculated intranasally with HSV-1 NS, not statistically significant compared to placebo control; MDD, mean day of death. *mg drug/kg per dose given twice daily. Table 3 . Effect of oral treatment with HDP-P-GCV or GCV on the mortality of BALB/c mice inoculated intranasally with HSV-1 NS, not statistically significant compared to placebo control; MDD, mean day of death. *mg drug/kg per dose given twice daily.
results were generally comparable to GCV based on mg/kg of drug administered.
Antiviral activity in MCMV-infected mice
Animals were treated orally with HDP-P-GCV or GCV at 30, 10 or 3 mg/kg twice daily for 7 days (Table 5 ). HDP-P-GCV was active at 30 mg/kg and 10 mg/kg twice daily, with reduction of mortality from 100 to 13 and 53%, respectively. GCV was also effective at 30 mg/kg and 10 mg/kg twice daily with mortality rates of 20 and 47%, respectively. Oncedaily dosing was somewhat less effective (data not shown).
Comparison of GCV and HDP-P-GCV corrected for molecular weight
To compare the effects of GCV and HDP-P-GCV, it is necessary to express the in vivo results on a molar basis since HDP-P-GCV has a higher molecular weight than GCV (MW 646 versus 254). We converted the oral daily doses of the two compounds to micromoles/kg/day and prepared figures expressing the percent mortality versus the drug dose. In the HSV-1 experiments we plotted a composite consisting of two experiments, averaged. For HSV-1 infection in mice, oral GCV and HDP-P-GCV are roughly equivalent in the two experiments when expressed on a molar basis. The 50% effective daily dose (ED 50 ) of GCV or HDP-P-GCV ranged from 3 to 18 micromoles/kg/day (Figure 2 ). In the MCMV infection, HDP-P-GCV was approximately 2.4-fold more effective than GCV with an ED 50 of 30 versus 78 micromoles/kg/day for GCV (Figure 3 ).
Antiviral activity of PCV and HDP-PCV in HSV-1-infected mice
We compared oral PCV with oral HDP-P-PCV in intranasal HSV-1 infection in mice (Table 6 ). PCV at a Table 5 . Effect of oral treatment with HDP-P-GCV or GCV on the mortality of BALB/c mice inoculated with MCMV NS, not statistically significant compared to placebo control; MDD, mean day of death. *mg drug/kg per dose given twice daily.
µ µ Figure 2 . Effect of oral ganciclovir and 1-O-hexadecylpropanediol-3-P-ganciclovir on mortality in HSV-1-infected mice Figure 3 . Effect of oral ganciclovir and 1-O-hexadecylpropanediol-3-P-ganciclovir on mortality in murine cytomegalovirus infection in mice
Total daily dose of the respective compounds is given in micromoles/kg/day. The figure is a composite of two experiments, which were averaged. Circles, HDP-P-GCV; squares, GCV.
Total daily dose of the respective compounds is given in micromoles/kg/day. The figure is a composite of two experiments, which were averaged. Symbols as in Figure 2 .
daily oral dose of 60 mg/kg (twice daily) provided a statistically significant reduction in mortality to 67% (P <0.05 versus placebo), but 120 mg/kg twice daily provided no additional benefit. In contrast, oral HDP-P-PCV gave a nearly linear dose response, and reduced mortality to 40% at 120 mg/kg twice daily (P<0.001 versus placebo). When the dose response data was expressed on a molar basis to take into account the higher formula weight of HDP-P-PCV, mortality decreased progressively with increasing doses of HDP-P-PCV to 40% at 00 micromoles/kg/day. However, the PCV response curve did not decline further after doses of 200 micromoles/kg/day.
Discussion
Poorly absorbed nucleosides such as acyclovir, ganciclovir and penciclovir may be converted to prodrugs to enhance oral bioavailability. For example, acyclovir and ganciclovir have been converted to their divalyl esters, valacyclovir and valganciclovir, resulting in improved plasma levels of the free nucleosides following oral administration of the prodrug (Beutner, 1995; Brown et al., 1999) . These compounds are hydrolyzed in the small intestine or in the liver to acyclovir or ganciclovir, respectively. Famciclovir is an acetylated double prodrug of penciclovir. Famciclovir is absorbed orally, quickly deacetylated and oxidized to penciclovir, a potent and selective anti-herpes simplex compound, which circulates and is responsible for the antiviral activity after intracellular conversion to PCV-triphosphate (Boike et al., 1994) . In contrast, HDP-P-GCV is believed to be absorbed intact in the small intestine in a manner similar to partially degraded phospholipids. HDP-P-GCV is 80% orally bioavailable in mice. A related acyclovir compound, 1-Ooctadecylglycero-3-phospho-ACV (ODGP-ACV) was shown to be 100% orally absorbed in mice versus 38% for ACV (Hostetler et al., 1997) . We hypothesize that enhanced oral absorption occurs because both ODGP-ACV and HDP-P-GCV are analogues related to lysophosphatidylcholine (LPC), a partially degraded phospholipid formed in the gastrointestinal tract by pancreatic phospholipase A 2 . Previous studies by Nilson & Borgstrom (1967) and Scow et al. (1967) showed that more than 60% of the LPC formed in the small intestine by the action of phospholipase A 2 is absorbed intact. In designing ganciclovir and acyclovir analogues for better oral absorption, we reasoned that the choline head group of lysophosphatidylcholine could be changed to a drug with preservation of oral absorption. In addition, we altered the ester at the 1-position to an ether to prevent deacylation by lysophospholipases present in pancreatic secretions. Cellular metabolism of the compounds in the target tissues produces the nucleoside analogues or their monophosphates, which are, in turn, converted to the antiviral nucleotide triphosphates. Table 6 . Effect of orally administered 1-O-Hexadecylpropanediol-3-P-penciclovir (HDP-P-PCV) or PCV on the mortality of BALB/c mice inoculated intranasally with HSV-1 NS, not statistically significant compared to placebo control; MDD, mean day of death. *mg drug/kg per dose given twice daily. †Tox., uninfected animals treated as stated above.
µ Figure 4 . Effect of oral penciclovir and 1-O-hexadecylpropanediol-3-P-penciclovir on mortality in HSV-1-infected mice Total daily dose of the respective compounds given in micromoles/kg/day. Symbols as in Figure 2 .
Activity of nucleoside analogues against CMV and HSV
In spite of the higher oral bioavailability of HDP-P-GCV versus GCV, HDP-P-GCV was equally effective on a molar basis with GCV against HSV-1 infection (Figure 2 ). However, it was about 2.5-fold more potent against MCMV (Figure 3) . The reasons for the discrepancy between HSV-1 and CMV are not immediately apparent. However, on a molar basis, HDP-P-PCV was also substantially more active than PCV given orally for HSV-1 (Figure 4) .
The hexadecyl propanediol ester of ganciclovir monophosphate is active and selective in HCMV-infected cells in vitro, but the antiviral activity in vitro against MCMV-infected mouse embryonic fibroblasts (MEF cells) was much lower than that of GCV. The reasons for the low antiviral activity in vitro are not clear, but it may be due to the lack of a full and active complement of lipidmetabolizing enzymes in MEF cells required for conversion of HDP-P-GCV to GCV-MP (or GCV). Previous in vitro metabolic studies from our laboratory, using radiolabelled 1-O-octadecylglycero-3-phospho-ACV, indicated that intracellular phosphodiesterases convert this closely related compound in part to ACV-MP in a phospholipase C-like reaction (Hostetler et al., 1997) . Thus, poor metabolism of the prodrug in embryonic fibroblasts may result in low antiviral activity. On the other hand, good metabolic conversion in intact mice provided substantial antiviral activity of HDP-P-GCV in mice infected with MCMV (Table 6 and Figure 3 ).
Penciclovir given orally had little effect on mortality from intranasal HSV-1 infection in mice. The largest dose of oral PCV, 120 mg/kg twice daily, provided a 33% reduction in mortality, similar to that provided by 60 mg/kg twice a day. In spite of its low antiviral activity in the HSV-1 plaque assay (Table 2) , HDP-P-PCV given orally provided a linear reduction in mortality from 87 to 40%, at 120 mg/kg twice daily. This suggests that oral absorption of the alkyl propanediol prodrug of penciclovir monophosphate is significantly greater than that of PCV, a drug known to have poor oral bioavailability.
In summary, HDP-P-GCV is an active and selective antiviral in HCMV-and HSV-infected cells in vitro. It is well absorbed orally in mice (80%), and provides excellent oral antiviral activity against acute HSV-1 and MCMV infection in mice. Oral HDP-P-PCV provided a more substantial reduction in mortality (60%) than oral PCV at higher molar doses. Further studies are indicated to assess the potential of these compounds as oral drugs for HSV-1 or HCMV infections.
